Local anesthesia external preparation and preparation method thereof

By using micropowder silicone as a drug carrier, adsorbing lidocaine and tetracaine, the problems of high irritability and poor stability of existing local anesthetics are solved, and higher drug stability and better clinical adaptability are achieved.

CN119033734APending Publication Date: 2024-11-29BEIJING TIDE PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310616597.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing local anesthetics have problems with high irritation and poor stability, especially tetracaine is prone to hydrolysis, which leads to inconvenience in clinical use and unstable efficacy.

Method used

Use micropowder silicone as a drug carrier. By mixing lidocaine and tetracaine with micropowder silicone, an eutectic mixture or solution is formed, and the solvent is removed by evaporation, the anesthetic agent is mixed with micropowder silicone to improve the stability of the drug and the drug loading amount. .

Benefits of technology

It significantly improves the stability and drug loading, reduces irritability, and improves the patient's adaptability and the convenience of clinical use of the agent.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033734A_ABST
    Figure CN119033734A_ABST
Patent Text Reader

Abstract

The present invention provides an external preparation for local anesthesia, which comprises a film-forming substrate and aerosil to which an anesthetic agent is adsorbed, and the anesthetic agent is lidocaine or a salt thereof, and tetracaine or a salt thereof. According to the invention, the balance between irritation and effectiveness is realized, and the stability of effective components is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine and relates to a local anesthetic external preparation for coating on the skin and a preparation method thereof. Background Art

[0002] Local anesthetics refer to drugs that can temporarily, completely, and reversibly block nerve conduction within a limited range of the human body, that is, they can make a part of the human body lose sensation without losing consciousness, so as to facilitate surgical operations. The fundamental difference between local anesthetics and general anesthetics is that after local anesthetics bind to certain specific parts of the sodium ion channels on the nerve membrane, the sodium ions passing through the sodium ion channels are reduced, thereby changing the nerve membrane potential, resulting in the conduction of nerve impulses being blocked, and ultimately achieving an anesthetic effect; while general anesthetics achieve an anesthetic effect by affecting the physical properties of the nerve membrane, such as the fluid properties and permeability of the membrane.

[0003] In the 1980s, the Swiss company Astra first launched a lidocaine-prilocaine compound cream (trade name EMLA, lidocaine 2.5%, prilocaine 2.5%). The specifications of the domestic compound lidocaine cream are the same as those of the EMLA cream. However, the EMLA ointment is inconvenient to use clinically (it needs to be covered with plastic wrap after application to prevent water evaporation and contamination of clothing) and has weak local anesthetic effect. The lidocaine-tetracaine compound cream (trade name Pliaglis), which was approved for marketing in the United States in 2006, contains the highest anesthetic ingredients (lidocaine 7%, tetracaine 7%) among all local anesthetic cream products. It is mainly used for local anesthesia of intact skin before superficial skin surgery in adults (such as dermal filler injections, pulsed dye laser treatment, facial laser resurfacing and laser-assisted tattoo removal).

[0004] Lidocaine or its pharmaceutical salt is an amide local anesthetic that stabilizes neuronal membranes by inhibiting the ion flux generated by impulse initiation and conduction. After transdermal administration, lidocaine or its pharmaceutical salt penetrates into the intact skin in an amount sufficient to produce analgesia but not enough to produce complete nerve block; tetracaine is an ester local anesthetic with a stronger local anesthetic effect, can penetrate the mucous membrane, and has a relatively rapid effect.

[0005]

[0006] Since the combination of the two in the Pliaglis preparation achieves a good effect, Pliaglis has been launched in many countries around the world. The biggest feature of Pliaglis is that after being applied to the skin, it will form a film as the surface moisture evaporates, and it can be easily peeled off after 30 minutes without any paste residue. It is convenient for clinical use and improves patient compliance.

[0007] However, Pliaglis is highly irritating, and the instructions state that the most common local reactions are erythema (47%), skin discoloration (16%), and edema (14%). The inventors found in their research that the cream (7% lidocaine + 7% tetracaine) prepared according to the Pliaglis prescription is indeed significantly irritating. When applied to the skin behind the ears of volunteers, the probability of irritation after 60 minutes is 95%, while the blank cream is non-irritating, indicating that the irritation is caused by the drug, and a formula with more appropriate efficacy and irritation needs to be developed.

[0008] In addition, more importantly, the local anesthetic drug components in the formula are unstable, especially tetracaine is easily hydrolyzed, resulting in poor stability of the entire formula. Therefore, the development of a more stable local anesthetic external preparation is still a technical problem that needs to be solved urgently. Summary of the invention

[0009] The purpose of the present invention is to overcome the shortcomings of existing pharmaceutical preparations in treatment and use, and to provide a safe, non-irritating and stable local anesthetic external preparation. Specifically, the present invention provides a local anesthetic external preparation, which comprises a film-forming matrix and micro-powder silica gel adsorbed with an anesthetic agent, wherein the anesthetic agent is lidocaine or its salt, and tetracaine or its salt. Relative to the total weight of the local anesthetic external preparation, by mass ratio, the content of lidocaine or its salt is 3-7%, the content of tetracaine or its salt is 3-5%, and the content of micro-powder silica gel is 0.02-10%. In this specification, if not specifically stated, the remainder is the film-forming matrix.

[0010] In a preferred embodiment of the present invention, the micropowder silica gel adsorbed with the anesthetic agent is prepared by mixing a low-melting mixture of lidocaine or its salt and tetracaine or its salt with the micropowder silica gel, or by mixing a mixed solution containing lidocaine or its salt and tetracaine or its salt with the micropowder silica gel, removing the solvent by evaporation, and mixing the anesthetic agent with the micropowder silica gel.

[0011] In a preferred embodiment of the present invention, the content of micro powder silica gel is 0.02-7.5%.

[0012] In a preferred embodiment of the present invention, the film-forming matrix is ​​a gel formed by a film-forming agent selected from polyvinyl alcohol, povidone, polyethylene oxide, and carbomer and water.

[0013] In a preferred embodiment of the present invention, the particle size of the micropowder silica gel is 1 to 40 μm, and the pore volume is greater than 1.0 ml / g.

[0014] In a preferred embodiment of the present invention, the film-forming matrix further contains one selected from the group consisting of a preservative, a moisturizer, an emulsifier, and a filler.

[0015] In a preferred embodiment of the present invention, the preservative is one or more of parabens, sorbic acid and its salts, hydroxybenzoic acid and its esters, and benzalkonium chloride, and the content is 0.05-0.2% by mass relative to the total weight of the local anesthetic external preparation.

[0016] In a preferred embodiment of the present invention, the moisturizing agent is one or more of glycerin, propylene glycol, butylene glycol, hexylene glycol, vaseline, and hyaluronic acid, and the content is 3-10% by mass relative to the total weight of the local anesthetic external preparation.

[0017] In a preferred embodiment of the present invention, the emulsifier is one or more of Tween, Span, polyoxyethylene castor oil, polyethylene glycol 54-hydrogenated castor oil, and polyethylene glycol 15-hydroxystearate, and the content is 3-6% by mass relative to the total weight of the local anesthetic external preparation.

[0018] In a preferred embodiment of the present invention, the filler is one or more of calcium sulfate, calcium carbonate, calcium bicarbonate, calcium phosphate, calcium hydrogen phosphate, aluminum hydroxide, titanium dioxide, mica powder, talc, kaolin, diatomaceous earth, and microcrystalline cellulose, and the content is 10 to 27% by mass relative to the total weight of the local anesthetic external preparation.

[0019] The present invention also provides a method for preparing the above-mentioned local anesthetic external preparation, which comprises the following steps:

[0020] In the drug-carrying particle forming step, lidocaine or its salt, tetracaine or its salt is dissolved in a reagent, and then micro-powder silica gel is added, stirred and mixed, and then the reagent is removed by rotary evaporation, so that the micro-powder silica gel adsorbs the drug to form drug carrier particles;

[0021] In a blank film-forming matrix forming step, a film-forming agent is added into water, heated and stirred to dissolve, and a blank gel is formed;

[0022] In the mixing step, the drug carrier particles are mixed with the blank gel to make them uniform, thereby obtaining a local anesthetic external preparation.

[0023] In a preferred embodiment of the present invention, the blank film-forming matrix forming process further comprises the steps of mixing and adding a preservative, a moisturizer, an emulsifier, and a filler into the blank gel and mixing them uniformly.

[0024] The topical anesthetic external preparation of the present invention can be used for local analgesia and / or for local anesthesia. The topical analgesia can be local analgesia for skin surface surgery. Specifically, the skin surface surgery can include: skin filler injection, pulse dye laser treatment, facial laser surface reconstruction or laser-assisted tattoo removal; the topical anesthesia can include skin local anesthesia; the skin local anesthesia includes: needle puncture or superficial surgical operation; the needle puncture includes: catheter placement or blood sampling.

[0025] Compared with the prior art, the present invention has the following obvious advantages:

[0026] 1. Micro-powder silica gel is used as a drug carrier to improve drug stability.

[0027] 2. The irritation of the formula of the present invention and the effect of the active ingredients are more balanced, and the patient adaptability is significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 It is micro powder silica gel Scanning electron micrograph of 244FP particles;

[0029] Figure 2 This is a scanning electron microscope image of micro powder silica gel SH-QX1 particles;

[0030] Figure 3 is the HPLC spectrum of prescription 1 (day 0);

[0031] Figure 4 is the HPLC spectrum of prescription 11 (day 0);

[0032] Figure 5 This is the HPLC spectrum of prescription 1 (40°C-30 days);

[0033] Figure 6 This is the HPLC spectrum of prescription 6 (40°C-30 days);

[0034] Figure 7 This is the HPLC spectrum of prescription 8 (40°C-30 days);

[0035] Figure 8 This is the HPLC spectrum of prescription 9 (40°C-30 days);

[0036] Fig. 9 This is the HPLC spectrum of prescription 11 (40°C-30 days);

[0037] Fig.10 This is the HPLC spectrum of prescription 12 (40°C-30 days);

[0038] Fig.11 This is the HPLC spectrum of prescription 13 (40°C-30 days). DETAILED DESCRIPTION

[0039] Each element of the present invention will be described in detail below.

[0040] The local anesthetic external preparation of the present invention comprises a film-forming matrix and micropowder silica gel adsorbed with an anesthetic agent, wherein the anesthetic agent is lidocaine or its salt, and tetracaine or its salt. Relative to the total weight of the local anesthetic external preparation, by mass ratio, the content of lidocaine or its salt is 3-7%, the content of tetracaine or its salt is 3-5%, and the content of micropowder silica gel is 0.02-10%.

[0041] Micro-powder silica gel is a commonly used pharmaceutical excipient with a large specific surface area (greater than 100m 2 / g), the uniform porous structure and the presence of surface silanol groups make it have a strong adsorption effect on drugs, and at the same time have good biocompatibility and pharmaceutical safety. It can be used as a glidant, anti-adhesive agent, absorbent for solid preparations and a clarifier, suspending agent, thickener, etc. for liquid preparations, and has been widely used in the fields of pharmaceutical preparations such as tablets, capsules, gels, suppositories, etc. In the present invention, the inventor unexpectedly found that the drug stability of the active ingredients can be significantly improved by using micro-powder silica gel as an adsorption carrier for lidocaine and tetracaine. In the high temperature accelerated experiment, the formula of lidocaine and tetracaine adsorbed by micro-powder silica gel has significantly improved stability compared with the active ingredients lidocaine and tetracaine directly mixed into the matrix component. This technical effect is not a conventional technical effect of micro-powder silica gel. The inventor speculates that it may be due to the following reasons: the eutectic mixture of the anesthetic agent in the present invention is mixed with the micro-powder silica gel to utilize the adsorption effect of the high surface area of ​​the micro-powder silica gel, or the micro-powder silica gel is dispersed in the lidocaine tetracaine solution, and the strong adsorption effect of the high surface area of ​​the micro-powder silica gel is efficiently utilized during the solvent volatilization process to adsorb the drug to the inner pores and surface of the silica gel particles, reducing the proportion of the drug in contact with water, thereby improving the drug stability; while the micro-powder silica gel adsorbs lidocaine and tetracaine, the surface silanol helps to inhibit hydrolysis. It should be noted that the above is only a speculated mechanism, and whether the speculation is correct does not affect the actual technical effect of the present invention. From the perspective of drug dispersion uniformity, drug stability, and obtaining a better stability effect, the method of dispersing micro-powder silica gel in the lidocaine tetracaine solution and then volatilizing the solvent in the above method is more preferred.

[0042] The micropowder silica gel can be selected to have an average particle size of 0.01 to 40 μm, preferably 0.01-20 μm, further preferably 0.01-10 μm, and most preferably 0.01-5 μm. The large particle size of the present invention is preferably 1-5 μm, further preferably 1-3 μm, and the small particle size of the present invention is preferably 0.01-1 μm, further preferably 0.02-0.5 μm. Some preferred schemes may further preferably be 0.02-0.05 μm. A medicinal micropowder silica gel with a pore volume greater than 0.6 ml / g can be used, preferably a medicinal micropowder silica gel with a pore volume greater than 1.0 ml / g, preferably greater than 1.2 ml / g, and it is difficult to achieve the effect of the present invention when the pore volume is less than 0.5 ml / g. If the particle size of the micropowder silica gel is less than 1 μm, the thickening effect is obvious, so that the amount added to the cream is small, resulting in a small amount of adsorbed drugs in the pores. At this time, the excessive content of the micropowder silica gel is not conducive to improving the stability of the drug, and the amount of small particle size micropowder silica gel should be appropriately reduced. Medicinal micro-powder silica gel can generally use silica produced by gas phase method, silica produced by precipitation method, etc. As long as the pore volume is large enough, the adsorption capacity is strong, and the particle size is greater than 1 micron, the technical effect of the present invention can be achieved by appropriately increasing the amount of micro-powder silica gel.

[0043] The increase of the content of micro powder silica gel is more conducive to stability. However, micro powder silica gel has a strong thickening effect. Increasing it blindly will make the preparation difficult to apply. As the content of micro powder silica gel, it is preferably 0.02-7.5% in the present invention, which can coordinate the stability and the physical and chemical properties of the preparation. From this point of view, it is further preferably 0.02%-5%, further preferably 0.02%-1.0%, and most preferably 0.2%-1.0%. As a more specific example of the content, for example, the content is 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9% or 1.0%. The most suitable embodiment of the present invention is to use medicinal micro powder silica gel with a particle size of 0.01-5μm, and use it in the range of 0.02%-1.0%, which can play a good role in improving stability. It can be used in combination with other fillers to adjust the consistency of the final dosage form to achieve a balance between stability and the physical and chemical properties of the preparation. When the average particle size of medicinal micropowder silica gel is greater than 1 μm, the technical effect of the present application can also be achieved by using it in the range of 0.02% to 5%. However, it is not limited to this implementation method and this content. Those skilled in the art can make a selection based on the gist of the present invention and the dosage form requirements.

[0044] Generally, commercially available micropowder silica gel can be used, for example, medical micropowder silica gel in the SYLOID series produced by Grace Corporation can be used.

[0045] The lidocaine or its salt and tetracaine or its salt in the present invention are no different from the prior art, and commonly used lidocaine hydrochloride, tetracaine hydrochloride, etc. can be used, but are not limited to these specific salts. The weight content of lidocaine and tetracaine is calculated according to the actual content of lidocaine and tetracaine in the salt (that is, if tetracaine hydrochloride is used, the weight of the hydrochloric acid part in the tetracaine hydrochloride is not calculated in the content of tetracaine).

[0046] In the present invention, in order to reduce the irritation of tetracaine, its concentration is preferably controlled below 5%. In view of the principle that the higher the drug concentration, the better the local anesthetic effect, the preferred compound ratio is lidocaine 7% + tetracaine 4%.

[0047] In order to achieve the technical effect of the present invention, the micropowder silica gel needs to fully adsorb lidocaine or its salt and tetracaine or its salt. In a preferred manner, lidocaine or its salt, tetracaine or its salt can be dissolved in a reagent, and then the micropowder silica gel is added, stirred and mixed, and then the reagent is removed by rotary evaporation, so that the micropowder silica gel adsorbs the drug to form drug carrier particles, thereby achieving the technical effect of high drug loading and stability.

[0048] However, the method of adsorbing lidocaine and tetracaine as the anesthetic active ingredients on the micro-powder silica gel in the present invention is not limited to this method. For example, lidocaine and tetracaine components can be mixed together, heated and melted to obtain a low eutectic mixture, and then mixed with micro-powder silica gel to allow the micro-powder silica gel to fully absorb the oily drug. Any method that can allow lidocaine and tetracaine as the anesthetic active ingredients to fully penetrate the surface and internal pores of micro-powder silica gel can achieve the preparation of micro-powder silica gel adsorbing anesthetic drugs.

[0049] The film-forming matrix of the present invention is no different from that in the prior art. The film-forming matrix can be, for example, a gel formed by a film-forming agent selected from polyvinyl alcohol, povidone, polyethylene oxide, carbomer, etc. and water. However, it is not limited to these. Any film-forming matrix can be used as long as it forms a film as the surface water evaporates after being applied to the skin and can be easily peeled off later without any paste residue. From the perspective of the compatibility with the micro-powder silica gel adsorbed with the anesthetic agent, polyvinyl alcohol is preferably used.

[0050] The film-forming matrix of the present invention may also contain various pharmaceutically acceptable additives without affecting the use effect of the present invention. Such additives include, for example, preservatives, moisturizers, emulsifiers, fillers, etc. For example, as a preservative, it may be one or more of parabens, sorbic acid and its salts, hydroxybenzoic acid and its salts, and benzalkonium chloride. Generally speaking, the content of the preservative may be 0.05 to 0.2% by mass relative to the total weight of the topical anesthetic preparation, but the content is not limited thereto, and whether it is contained and the content are both selectable by those skilled in the art as needed.

[0051] The reagent for dissolving the drug may be, for example, one or more of methanol, ethanol, isopropanol, and chloroform.

[0052] As a moisturizer, for example, it can be one or more of glycerin, propylene glycol, butylene glycol, hexylene glycol, vaseline, and hyaluronic acid, and the content is 3 to 10% by mass relative to the total weight of the local anesthetic external preparation. However, this content is not limited, and whether to contain it and the content are all selectable by those skilled in the art according to needs.

[0053] As an emulsifier, for example, it can be one or more of Tween, Span, polyoxyethylene castor oil, polyethylene glycol 54-hydrogenated castor oil, and polyethylene glycol 15-hydroxystearate, and the content is 3-6% by mass relative to the total weight of the local anesthetic external preparation. However, this content is not limited, and whether to contain it and the content are all selectable by those skilled in the art according to needs.

[0054] As fillers, for example, one or more of calcium sulfate, calcium carbonate, calcium bicarbonate, calcium phosphate, calcium hydrogen phosphate, aluminum hydroxide, titanium dioxide, mica powder, talc, kaolin, diatomaceous earth, and microcrystalline cellulose may be used, and the content thereof may be 10 to 27% by mass relative to the total weight of the topical anesthetic preparation, but the content thereof is not limited, and whether or not to contain the fillers and the content thereof may be selected by those skilled in the art as required. It should be noted that fillers are used to change the relevant physical and chemical properties of the dosage form of the present invention, and micropowder silica gel may also be used as an additive, however, when micropowder silica gel is used as an additive, it is different from the micropowder silica gel used as a drug carrier in the present invention, and the amount of micropowder silica gel used is not included in the content of micropowder silica gel in the present invention, but is included in the content of the additive.

[0055] The method for preparing the local anesthetic external preparation may include the following steps:

[0056] Add the drug to the reagent, stir to dissolve, then add micro-powdered silica gel, stir to mix and disperse evenly, and remove the reagent by rotary evaporation to obtain drug-loaded powder particles;

[0057] In a blank film-forming matrix forming step, a film-forming agent is added into water, heated and stirred to dissolve, and a blank gel is formed;

[0058] In the mixing step, the drug carrier particles are mixed with the blank gel to make them uniform, thereby obtaining a local anesthetic external preparation.

[0059] The drug-loaded particle formation process in the above process is a characteristic preparation step. Based on this operation method, the obtained lidocaine or its salt, tetracaine or its salt is fully embedded in the micro-powder silica gel, which can improve the stability of the active ingredients.

[0060] The blank film-forming matrix forming process also includes the steps of mixing and adding preservatives, moisturizers, emulsifiers, and fillers into the blank gel and mixing them uniformly.

[0061] The local anesthetic external preparation of the present invention can be used for any form of topical local anesthesia and local analgesia. The local analgesia can be used for local analgesia for skin surface surgery. Specifically, the skin surface surgery can include: skin filler injection, pulse dye laser treatment, facial laser surface reconstruction or laser-assisted tattoo removal; the local anesthesia can include skin local anesthesia; the skin local anesthesia includes: needle puncture or superficial surgical operation; the needle puncture includes: catheter insertion or blood sampling.

[0062] In order to further illustrate the various elements of the present invention, the following embodiments are provided for illustration; however, the protection scope of the present invention is not limited to the following embodiments.

[0063] Example

[0064] Example 1 - Screening of lidocaine / tetracaine ratios to reduce irritation

[0065] A prescription was designed, wherein the total weight of each prescription sample was 100 g.

[0066]

[0067] The preparation process is as follows:

[0068] 1. Take the prescribed amount of lidocaine and tetracaine, mix them together, heat and melt them in a water bath at 60°C to obtain a eutectic mixture;

[0069] 2. Add methylparaben and propylparaben to purified water, stir and dissolve in a water bath at 80°C, then add polyvinyl alcohol, stir and dissolve, cool to room temperature, add Span 40, vaseline and calcium hydrogen phosphate, stir and mix evenly to obtain a blank cream.

[0070] 3. Mix the eutectic mixture and the blank cream together and stir evenly to obtain.

[0071] Example 2 - Comparison of human irritation

[0072] Twenty healthy volunteers (10 males and 10 females, aged 25-40 years) were recruited to apply a small amount of cream behind both ears, covering an area of ​​4.0 cm 2 The application amount is about 0.15g. After 30 minutes, peel off the film and observe whether there is erythema, discoloration or edema at the application site. Each test is 7 days apart. The results are as follows:

[0073] Prescription 1 Prescription 2 Prescription 3 Prescription 4 Prescription 5 Prescription 6 Lidocaine + Tetracaine 7%+7% blank 3%+3% 4%+4% 5%+5% 7%+4% Number of erythema cases 6 0 0 0 2 0 Number of discoloration cases 3 0 0 0 2 0 Number of edema cases 0 0 0 0 0 0 Irritation incidence 45% 0% 0% 0% 20% 0%

[0074] To further evaluate the irritation, the amount of cream applied per unit area and the application time were doubled. Twenty healthy volunteers (10 males and 10 females, aged 25-40 years) were recruited again and the creams of prescription 1 and prescription 6 were applied behind the ears on both sides, with an application area of ​​4.0 cm 2 The application amount is about 0.30g, and the application time is 60min. Peel off the formed film and observe whether there is erythema, discoloration or edema at the application site. The results are as follows:

[0075] Prescription 1 Prescription 6 Lidocaine + Tetracaine 7%+7% 7%+4% Number of erythema cases 15 2 Number of discoloration cases 3 1 Number of edema cases 1 0 Irritation incidence 95% 15%

[0076] Conclusion: Under low-dose administration, tetracaine concentration ≥ 5% showed a certain irritation, while lidocaine did not produce irritation under the condition of 7% concentration. The preferred concentrations of lidocaine and tetracaine were 7% and 4%, respectively. Under high-dose administration, the irritation of 7% lidocaine + 4% tetracaine cream was much lower than that of 7% lidocaine + 7% tetracaine cream.

[0077] Example 3 Comparison of micropowder silica gel with different pore volumes

[0078] We found in the experiment that the compound cream has a certain fluidity, 0.30g / 4.0cm on the skin 2 In the case of smearing, when the film is peeled off after 1.0h, it can be found that the cream of prescription 6 will produce a downward extension displacement of about 1.0mm due to gravity during the film formation process. Micro-powder silica gel, as a thickener, can increase the viscosity of the system and slow down the flow of the paste.

[0079] In addition, the larger the pore volume of micro-powder silica gel, the more it is used, the more drugs can be encapsulated in the pores, and the better the drug stability. Two types of micro-powder silica gel with different pore volumes are selected, one with high pore volume and the model 244FP (batch number 1000348580), the measured pore volume is 1.48ml / g, and the specific surface area is relatively large, which is 354.3m 2 / g. The other is low pore volume micro powder silica gel, model SH-QX1 (batch number 160123), with a measured pore volume of 0.46ml / g and a specific surface area of ​​228.8m 2 / g. The particle morphology is as follows Figure 1 ( 244FP particles scanning electron microscopy image) and Figure 2 (SH-QX1 particle scanning electron microscope image) is shown. From the electron microscope image results, we can see that 244FP is an irregular micron-sized particle, and most of the particles are between 1.0 and 5.0 μm in size. SH-QX1 particles are relatively uniform soft agglomerates of nano-spherical particles, with a particle size of about 20 to 30 nm.

[0080] The designed prescription is as follows, where the total weight of each prescription sample is 100 g.

[0081]

[0082] Add lidocaine and tetracaine to 100 g of ethanol, stir to dissolve, then add micro-powdered silica gel, stir to mix and disperse evenly, and remove ethanol by rotary evaporation at 50°C to obtain drug-loaded powder particles;

[0083] Add polyvinyl alcohol into water, heat and stir in a water bath at 60°C to dissolve, then add benzalkonium chloride, Span 60, vaseline and calcium sulfate, stir evenly to form a blank gel;

[0084] The drug-loaded powder particles are mixed with the blank gel, and stirred evenly to obtain a cream.

[0085] Take a small amount of cream sample and apply it on the outer side of the upper arm of the volunteers (application amount 0.30g, application area 4cm 2 ), to examine the spreadability and fluidity of the cream, the results are as follows:

[0086]

[0087] When the dosage of large-particle silica gel is 0.2%, it can effectively slow down the flow of the cream; when it is 5%, the cream is fine; as the dosage increases to 10%, the thickening effect is stronger, resulting in a higher viscosity of the cream and poor uniform application. However, the thickening effect of small-particle silica gel is relatively strong, but when it is 5%, the cream viscosity is too high and cannot be applied evenly.

[0088] Example 4 Stability Test

[0089] A small amount of pastes of prescription 1, prescription 6, prescription 8, prescription 9, and prescriptions 11-13 were taken, sealed, and placed in a 40°C oven for accelerated testing. After 30 days, the pastes were taken out and analyzed for related substances by high performance liquid chromatography.

[0090] The analysis method is as follows (this method is the current version of the Chinese Pharmacopoeia method for related substances of lidocaine hydrochloride. The retention time of tetracaine is about 14.8 minutes, and the retention time of lidocaine is about 12.7 minutes):

[0091]

[0092] The analysis results are as follows:

[0093] prescription Micro powder silica gel content% Total impurities on day 0 40℃-30 days Total impurities % 1 0 0.63 (see Figure 3 ) 4.84 (See Figure 5 ) 6 0 0.45 3.17 (See Figure 6 ) 8 0.2(small particle size) 0.44 2.80 (See Figure 7 ) 9 1(small particle size) 0.42 2.11 (See Figure 8 ) 11 5(large particle size) 0.31 (see Figure 4 ) 1.73 (see Fig. 9 ) 12 7.5 (large particle size) 0.33 1.31 (See Fig.10 ) 13 10(large particle size) 0.35 1.18 (See Fig.11 )

[0094] Reference Figures 3 to 11, which shows that when the system does not contain micro-powder silica gel, the stability of the preparation is poor. After 30 days of accelerated temperature at 40℃, the total impurities in prescription 1 were the highest (7%) due to the highest concentration of tetracaine, which was 4.84%. When the amount of tetracaine was reduced to 4%, the total impurities in prescription 6 were reduced to 3.17%. With the increase of the amount of micro-powder silica gel, the proportion of drugs attached to the pores increased, the stability of the preparation was improved, and the total impurities were greatly reduced.

[0095] Example 5 - Film Forming Agent Adaptability

[0096] Micropowder silica gel (brand SYLOID, model 244FP, batch number 1000348580) was selected as the drug carrier, and the total weight of each prescription sample was 100 g.

[0097]

[0098] Add lidocaine and tetracaine to 100 g of ethanol, stir to dissolve, then add micro-powdered silica gel, stir to mix and disperse evenly, and remove ethanol by rotary evaporation at 50°C to obtain drug-loaded powder particles;

[0099] Add the film-forming agent into water, heat and stir in a water bath at 60°C to dissolve, then add benzalkonium chloride, glycerol, Tween 80, and talcum powder, stir evenly to form a blank gel;

[0100] The drug-loaded powder particles are mixed with the blank gel, and stirred evenly to obtain a cream.

[0101] Apply a small amount of cream on the back of the volunteer's hand and observe after 30 minutes. The results are as follows:

[0102] prescription Film former Application Film formation 14 Polyvinyl alcohol The paste is fine and can be applied evenly Good film-forming property and can be easily peeled off 15 Povidone K90 The paste is fine and can be applied evenly Can form film, but the system is cracked 16 Hydroxypropyl methylcellulose E5 The paste is fine and can be applied evenly Can form film, but the system is cracked 17 gelatin The paste is hard and difficult to apply /

[0103] The film-forming matrix obtained by combining with polyvinyl alcohol as a film-forming agent is suitable for the drug-loaded powder particles of the present invention and has the best effect.

[0104] The present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A local anesthetic external preparation, comprising a film-forming matrix and micropowder silica gel adsorbed with an anesthetic agent, wherein the anesthetic agent is lidocaine or a salt thereof, and tetracaine or a salt thereof, and relative to the total weight of the local anesthetic external preparation, by mass ratio, the content of lidocaine or a salt thereof is 3-7%, the content of tetracaine or a salt thereof is 3-5%, and the content of micropowder silica gel is 0.02-10%.

2. The local anesthetic external preparation according to claim 1, wherein The content of micro powder silica gel is 0.02-7.5%.

3. The local anesthetic external preparation according to claim 1, wherein The micronized silica gel adsorbed with the anesthetic agent is prepared by mixing a eutectic mixture of lidocaine or its salt and tetracaine or its salt with micronized silica gel, or, The anesthetic agent is prepared by mixing a mixed solution containing lidocaine or a salt thereof and tetracaine or a salt thereof with fine powder silica gel, removing the solvent by evaporation, and mixing the anesthetic agent with the fine powder silica gel.

4. The local anesthetic external preparation according to claim 1, wherein The film-forming matrix is ​​a gel formed by a film-forming agent selected from polyvinyl alcohol, povidone, polyoxyethylene and carbomer and water.

5. The local anesthetic external preparation according to claim 1, wherein The particle size of the micropowder silica gel is 1-40 μm, and the pore capacity is greater than 1.0 ml / g.

6. The local anesthetic external preparation according to claim 1, wherein The film-forming matrix also contains one selected from the group consisting of a preservative, a moisturizer, an emulsifier, and a filler.

7. The local anesthetic external preparation according to claim 6, wherein The preservative is one or more of parabens, sorbic acid and its salts, hydroxybenzoic acid and its esters, and benzalkonium chloride, and the content of the preservative is 0.05-0.2% by mass relative to the total weight of the local anesthetic external preparation.

8. The local anesthetic external preparation according to claim 6, wherein The moisturizing agent is one or more of glycerin, propylene glycol, butylene glycol, hexylene glycol, vaseline, and hyaluronic acid, and the content is 3-10% by mass relative to the total weight of the local anesthetic external preparation.

9. The local anesthetic external preparation according to claim 6, wherein The emulsifier is one or more of Tween, Span, polyoxyethylene castor oil, polyethylene glycol 54-hydrogenated castor oil, and polyethylene glycol 15-hydroxystearate, and the content is 3-6% by mass relative to the total weight of the local anesthetic external preparation.

10. The local anesthetic external preparation according to claim 6, wherein The filler is one or more of calcium sulfate, calcium carbonate, calcium bicarbonate, calcium phosphate, calcium hydrogen phosphate, aluminum hydroxide, titanium dioxide, mica powder, talc, kaolin, diatomaceous earth, and microcrystalline cellulose, and its content is 10-27% by mass relative to the total weight of the local anesthetic external preparation.

11. The local anesthetic external preparation according to any one of claims 1 to 10, which is used for local analgesia and / or local anesthesia.

12. The local anesthetic external preparation according to claim 11, wherein The local analgesia is local analgesia for skin surface surgery; the skin surface surgery includes: skin filler injection, pulse dye laser treatment, facial laser resurfacing or laser-assisted tattoo removal; The use for local anesthesia includes use for skin local anesthesia; the skin local anesthesia includes: needle puncture or superficial surgical operation; the needle puncture includes: catheter placement or blood sampling.

13. The method for preparing the local anesthetic external preparation according to claim 1, comprising the following steps: In the drug-carrying particle forming step, lidocaine or its salt and tetracaine or its salt are heated and mixed to form a eutectic mixture, and then micro-powdered silica gel is added and stirred to make it absorb the eutectic mixture to form drug carrier particles; In a blank film-forming matrix forming step, a film-forming agent is added into water, heated and stirred to dissolve, and a blank gel is formed; In the mixing step, the drug carrier particles are mixed with the blank gel to make them uniform, thereby obtaining a local anesthetic external preparation.

14. The method for preparing the local anesthetic external preparation according to claim 1, comprising the following steps: The drug-carrying particle forming step comprises dissolving lidocaine or its salt, tetracaine or its salt in an organic solvent to form a solution, then adding micro-powdered silica gel, stirring to make it absorb the above solution, and then volatilizing the organic solvent to form drug carrier particles; In a blank film-forming matrix forming step, a film-forming agent is added into water, heated and stirred to dissolve, and a blank gel is formed; In the mixing step, the drug carrier particles are mixed with the blank gel to make them uniform, thereby obtaining a local anesthetic external preparation.

15. The method for preparing the local anesthetic external preparation according to claim 13 or 14, wherein: The blank film-forming matrix forming process also includes the steps of mixing and adding preservatives, moisturizers, emulsifiers, and fillers into the blank gel and mixing them uniformly.